ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Alpelisib

Also written as “BYL719”, “alpelisib” and “BYL719 as film-coated (FC) whole tablets”.

Its studies are mostly in Breast Neoplasms · Squamous Cell Carcinoma of Head and Neck · Neoplasms · Ovarian Neoplasms · Lymphatic Abnormalities, led by 4 companies.

Drug pageAlpelisib: every studyAll 85 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 21, 202237 company-led studies, 11 open or runningNext primary completion: Jan 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis3310 open or runningphase 4since Nov 21, 2022Oct 6, 2010Jan 28, 2027phase 3 · NCT05038735
Pfizerits history only20 open or runningphase 2since Oct 30, 2012Oct 6, 2011none ahead
Criteriumits history only11 open or runningphase 2since Dec 27, 2021Dec 27, 2021none ahead
Kura Oncologyits history only10 open or runningphase 2since Jul 27, 2021Jul 27, 2021none ahead

Also a collaborator on its studies: ImmunityBio.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since Oct 6, 2010.

  1. Dec 12, 2019Phase 3 study in Advanced HER2+Breast CancerNCT04208178 · 19 enrolled · United States, Belgium, China and more
  2. Jan 30, 2020Phase 3 study in Triple Negative Breast NeoplasmsNCT04251533 · 137 enrolled · United States, Argentina, Australia and more
  3. Aug 19, 2020Phase 2 study in Advanced Breast CancerNCT04524000 · 24 enrolled · Japan
  4. Sep 3, 2020Phase 2 study in Breast NeoplasmsNCT04544189 · 69 enrolled · China
  5. Oct 14, 2020Phase 2 study in PIK3CA-related Overgrowth Spectrum (PROS)NCT04589650 · 236 enrolled · United States, Canada, China and more
  6. Jan 25, 2021Phase 3 study in Ovarian NeoplasmsNCT04729387 · 358 enrolled · United States, Argentina, Australia and more
  7. Apr 21, 2021Phase 2 study in Advanced Breast CancerNCT04862143 · 2 enrolled · Sweden
  8. Jul 19, 2021Phase 2 study in PIK3CA-related Overgrowth Spectrum (PROS)NCT04980833 · 41 enrolled · United States, France, Ireland and more
  9. Sep 1, 2021Phase 3 study in Breast NeoplasmsNCT05038735 · 210 enrolled · Belgium, Bulgaria, Canada and more
  10. Nov 21, 2022Phase 4 study in Multiple Endocrine Neoplasia Type 1NCT05631795 · 40 enrolled · India
  11. Jul 4, 2023Phase 3 study in Lymphatic AbnormalitiesNCT05948943 · 232 planned · United States, Argentina, Australia and more
  12. May 21, 2025Phase 2 study in PIK3CA-related Overgrowth Spectrum (PROS)NCT06997588 · 140 planned · United States, Australia, Austria and more
  13. Jun 25, 2026Phase 2 study in Breast NeoplasmsNCT07679269 · 51 planned
  14. Oct 5, 2026Primary completion moved from 2028-08-02 to 2029-01-29Date moved laterphase 2 · +6 months · NCT06997588

Ahead

  1. Jan 28, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05038735
  2. Jan 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT04544189
  3. Feb 26, 2027Primary completion: phase 2 study in Advanced Breast CancerNCT04524000
  4. Feb 26, 2027Primary completion: phase 3 study in Advanced HER2+Breast CancerNCT04208178

TargetBeta

PIK3CA →read by rule
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
inavolisibruleHoffmann-La Rochephase 320
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 33 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07679269Breast Neoplasms2Not yet recruitingMar 23, 203251
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS) · United States, Australia, Austria and more2RecruitingJan 29, 2029140
NCT05948943Lymphatic Abnormalities · United States, Argentina, Australia and more3RecruitingMay 31, 2028232
NCT05631795Multiple Endocrine Neoplasia Type 1 · India4CompletedJun 12, 202540
NCT05038735Breast Neoplasms · Belgium, Bulgaria, Canada and more3Active, not recruitingJan 28, 2027210
NCT04980833PIK3CA-related Overgrowth Spectrum (PROS) · United States, France, Ireland and more2Active, not recruitingJun 22, 202741
NCT04862143Advanced Breast Cancer · Sweden2TerminatedSep 19, 20222
NCT04729387Ovarian Neoplasms · United States, Argentina, Australia and more3TerminatedApr 21, 2023358
NCT04589650PIK3CA-related Overgrowth Spectrum (PROS) · United States, Canada, China and more2Active, not recruitingMar 20, 2024236
NCT04544189Breast Neoplasms · China2Active, not recruitingJan 29, 202769
NCT04524000Advanced Breast Cancer · Japan2Active, not recruitingFeb 26, 202724
NCT04251533Triple Negative Breast Neoplasms · United States, Argentina, Australia and more3TerminatedMay 31, 2023137
NCT04208178Advanced HER2+Breast Cancer · United States, Belgium, China and more3Active, not recruitingFeb 26, 202719
NCT03439046Breast Neoplasms · Italy3TerminatedDec 11, 2023287
NCT03056755Breast Neoplasms · United States, Argentina, Belgium and more2CompletedJun 14, 2021383
NCT02624557Hepatic Impairment · United States1CompletedOct 1, 201723
NCT02437318Breast Neoplasms · United States, Argentina, Australia and more3CompletedJun 12, 2018572
NCT02276027Adenocarcinoma of Lung · China2CompletedOct 15, 201966
NCT02144038Recurrence · United States, Australia, Germany and more1CompletedOct 28, 201520
NCT02088684Breast Neoplasms · United States, France, Italy and more1CompletedApr 17, 201870
NCT02077933Neoplasms · United States, France, Germany and more1CompletedApr 12, 201979
NCT02051751Neoplasms · United States, France, Italy and more1CompletedAug 19, 201619
NCT02058381Pre-menopausal Breast Cancer · Hong Kong, Korea, Republic of, Taiwan and more1CompletedJun 19, 201840
NCT01928459Breast Neoplasms · United States, Australia, Belgium and more1CompletedAug 201662
NCT01923168Breast Neoplasms · United States, Australia, Austria and more2CompletedJul 7, 2017340
NCT01872260Breast Neoplasms · United States, Australia, France and more2Active, not recruitingFeb 26, 2027259
NCT01822613Esophageal Squamous Cell Carcinoma · United States, Belgium, Canada and more1CompletedJun 3, 201648
NCT017359683rd Line GIST · United States, Belgium, France and more1CompletedOct 19, 201856
NCT01708161Breast Neoplasms · United States, Belgium, Canada and more2TerminatedDec 26, 201447
NCT01613950Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein · United States, Germany, Japan and more1CompletedMar 201418
NCT01602315Squamous Cell Carcinoma of Head and Neck · United States, Australia, Canada and more2TerminatedSep 16, 2016179
NCT01387321Advanced Solid Tumor · Japan1CompletedNov 25, 201533
NCT01219699Advanced Solid Tumors With an Alteration of the PIK3CA Gene · United States, Germany, Netherlands and more1CompletedFeb 5, 2015221

How it is read

Names in the registry

  • “Alpelisib”, 18 entries
  • “BYL719”, 13 entries
  • “alpelisib”, 3 entries
  • “BYL719 as film-coated (FC) whole tablets”, 1 entry
  • “BYL719 as dispersible tablets (DT)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.